Risk Prediction for Neurological Disorders, Prodia Provides NEUROgenomics Test

JAKARTA, 19 July 2021 – Technological advances in the biomolecular field, triggered by the completion of the human genome project, have an impact on the increasingly advanced development of diagnostics in the world. The direction of the medical world is no longer curative but more upstream, namely predictive medicine. Predictive medicine needs to be supported by predictive diagnostics, which utilizes human genome profiling to predict various diseases. After previously launching various predictive tests such as CArisk, DIArisk, VASCULArisk, IMMUNErisk, Prodia Wellness Genomics, Prodia Bone Muscle and Joints Genomics, Prodia Nutrigenomics, Skin and Hair Genomics, the NEUROgenomics is now being launched.

Based on Basic Health Research data, the prevalence rate of neurological diseases, especially stroke, reaches 15.4% of the total population in Indonesia. The high prevalence of neurological diseases in Indonesia has prompted PT Prodia Widyahusada Tbk (Stock Code: PRDA) to provide medical test that is able to predict the risk of neurological disorders based on a person's genetic profile, named NEUROgenomics. NEUROgenomics is a genomic testing used to identify a person's genetic susceptibility to diseases related to neurological disorders such as Alzheimer's disease, Amyotrophic lateral sclerosis, Bipolar disorder, Epilepsy, Intracranial aneurysm, Migraine, Multiple sclerosis, Parkinson's disease, Schizophrenia, and Stroke. The test analyzes more than 109 variants and 85 genes.

Product Manager of Prodia Trilis Yulianti said, “Prodia's initiative in launching the NEUROgenomics test is in line with our commitment to support the next generation medicine that is personal, predictive, preventive and participatory (4P). NEUROgenomics calculates the risk of gene variants in a personalized manner so that each individual knows the risk and can personally determine the prevention of neurological diseases. We hope that this testing can be a kind of alarm for individuals to be more motivated to make efforts to prevent the emergence of neurological diseases in the future,” Trilis explained at Prodia Tower Jakarta (19/7).

Various researches to date show that the emergence of disease is influenced by the interaction between genetics, lifestyle and other medical conditions. This means that if a person is genetically susceptible to certain neurological disorders or diseases but the lifestyle and diet are well maintained, the emergence of the disease can be prevented and vice versa, even though a person has a low neurological genetic risk but has a high-risk diet for metabolic disorders, it can lead to neurological disorders.

On the results of the NEUROgenomics examination, the overall risk score will provide a conclusion about a person's risk of a disease based on the gene that is tested as a whole. The overall risk score is divided into four types: High Risk, for those who have a higher risk of disease than the population average; Potential Risk, for those who have a slightly higher risk of disease than the population average; Average Risk, for those who have the same risk for the occurrence of disease compared to the population average; and Low Risk, for those who have a lower risk of disease than the population average.

The NEUROgenomics examination is a supporting test for predictive medicine, which is suggested for people who have the family of patients with a history of neurological disorders or those who have neurological disorders and anyone who wants to know whether they are genetically susceptible to neurological diseases.

The NEUROgenomics is performed at the Prodia Genome Center located on the 3rd Floor of Prodia Tower, Jl. Kramat Raya No, 150, Central Jakarta, meanwhile, blood sampling can be collected at all Prodia branches and outlets throughout Indonesia.

*****

About PT Prodia Widyahusada Tbk

Prodia Clinical Laboratory was initially established in Solo on 7 May 1973 by a group of idealist pharmacists. From the very first, Andi Wijaya, along with the other founders have been committed to present the best test results with wholehearted services.

As the market leader, since 2012 Prodia has been the only laboratory and clinic in Indonesia accredited by the College of American Pathologists (CAP). It implies that Prodia' s test results are equal in quality to those obtained from other international laboratories.

On 7 December 2016, the Indonesia Stock Exchange officially listed the initial public offering of Prodia as the 15th issuer in 2016, with the ticker symbol 'PRDA'. In that corporate action, Prodia offered 187.5 million shares. Accordingly, the fund raised from the Company' s initial public offering (IPO) was Rp1.22 trillion.

Currently, Prodia has had the service network that incorporates 269 outlets, across 127 cities and 34 provinces in Indonesia, Prodia Health Care (PHC) - a personalized medicine-based wellness clinic - and specialty clinics, including Prodia Children' s Health Centre (PCHC), Prodia Women' s Health Centre (PWHC), and Prodia Senior Health Centre (PSHC).

Prodia has launched Kontak Prodia 1500-830 and the online-based virtual personal assistant Tanya Prodia (TANIA). TANIA can be accessed by anyone, especially Prodia customers directly anytime and anywhere online including via LINE: @prodia.id, Telegram: @prodia.id, Facebook Messenger: @prodia.id and Prodia Website: www.prodia.co.id.

For more information, please visit www.prodia.co.id or contact:  

Marina Eka Amalia   

Legal Head & Corporate Secretary

PT Prodia Widyahusada Tbk. 

Ph.       +62-21-3144182 ext 3816

Email     corporate.secretary@prodia.co.id